| Ticker: CGCP | 540 Oakmead Parkway | |
| Exchange: NASDAQ-National Market | Sunnyvale, California 94086 | |
| Industry: Manufacturing | (408) 328-8500 |
| Type of Shares: | Common Shares | Filing Date: | 4/19/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 5/21/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $14.00 - $16.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $20.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.40 | |
| Offering Amount: | $45,000,000 | Selling: | $0.84 | |
| Expenses: | $1,000,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,927,528 |
| Manager | Tier | Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-2000 |
| Montgomery Securities | Co-manager | 4156272220 |
| Piper Jaffray Incorporated | Co-manager | (612) 342-6000 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.00 | $0.63 | $0.00 | Assets: | $14.73 |
| Net Income: | -$5.30 | -$1.88 | -$0.63 | Liabilities: | $1.35 |
| EPS: | -$0.62 | -$0.22 | -$0.07 | Equity: | $13.38 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is developing proprietary methods and systems, including disposable components, to perform both surgical and catheter-based percutaneous transmyocardial revascularization (TMR). TMR is used to treat patients with severe coronary artery disease who suffer from recurrent debilitating chest pain. Unlike coronary artery bypass grafting (CABG) and precutaneous transolumnial coronary angioplasty (PTCA), which are used to bypass, reopen or widen blocked or narrowed arteries, TMR involves the use of laser energy to create typically between 15 and 30 channels in the oxygen-starved regions of the heart muscle. Reports of clinical studies, including preliminary findings in Circulation, a peer-reviewed journal, indicate that groups of patients treated with TMR have experienced significant reductions in chest pain, improved exercise tolerance and increased myocardial blood flow. The company believes that these reported benefits of TMR are associated with angiogenesis, the formation of new blood vessels. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund research and development efforts, fund clinical trials, expand sales and marketing activities, expand and develop manufacturing and other facilities and for working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.